April 16, 2020 10:15 AM EDT
R&D

In­ter­im da­ta on Vir's Al­ny­lam-part­nered RNAi hep B drug sug­gest ef­fi­ca­cy is broad­ly on par with J&J, Ar­row­head ri­val — an­a­lysts

Natalie Grover

Reporter

With ef­forts un­der­way to de­vel­op an an­ti­dote for Covid-19, Vir Ther­a­peu­tics and its chief George Scan­gos, a Bio­gen vet­er­an who has been tapped to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times